首页> 外国专利> HUMAN CONJUNCTIVA CELLULAR CULTURE CHANG ATCC-CCL 20.2 FOR PREVENTION OF THE PHENOMENON OF TOXICITY OF EYE INSTILLATION IN CASE OF THE JOINT APPLICATION OF MEDICINAL DRUGS

HUMAN CONJUNCTIVA CELLULAR CULTURE CHANG ATCC-CCL 20.2 FOR PREVENTION OF THE PHENOMENON OF TOXICITY OF EYE INSTILLATION IN CASE OF THE JOINT APPLICATION OF MEDICINAL DRUGS

机译：人结膜细胞培养改变ATCC-CCL 20.2联合使用药用药物时预防眼部感染的毒性现象

页面导航

摘要
著录项
相似文献

摘要

FIELD: biotechnologies.;SUBSTANCE: invention refers to biotechnology. Specifically, the invention refers to preventing the phenomenon of enhancing the toxicity of ocular instillations when a combination of drugs is jointly applied. Conjunctiva cell cultures are used, while selecting the optimal concentrations of eye preparations by means of evaluating the metabolic activity of the conjunctiva cell culture qualitatively through a morphological evaluation using visual control and quantitatively using the MTT test. Assessment is carried out in case of influence of these eye preparations or their combinations in different concentrations. Production of cytokines is evaluated in comparison with the transcription level control after 48 hours of incubation with these eye preparations or of the combination thereof at the selected concentration. Non-processed conjunctiva cell culture is used as the control means. Increase in cytokine production indicates the absence of the increase in the toxicity of eye instillations during the joint use of drugs, which allows the use of the proven combination of drugs for the treatment of inflammatory diseases of the conjunctiva and of the cornea.;EFFECT: invention can be used in order to prevent the phenomenon of enhancing the toxicity of ocular instillations, when the combination of drugs is jointly applied.;5 cl, 3 dwg, 1 ex, 3 tbl

机译：领域：生物技术。实体：发明是指生物技术。具体地，本发明涉及防止当联合使用药物组合时增强滴眼剂毒性的现象。使用结膜细胞培养物，同时通过使用视觉控制通过形态学评估定性评估结膜细胞培养物的代谢活性，并使用MTT测试定量地选择最佳浓度的眼用制剂。如果这些眼睛制剂或它们的组合浓度不同，则进行评估。与这些眼部制剂或其选定浓度的组合孵育48小时后，与转录水平对照进行比较，评估细胞因子的产生。未处理的结膜细胞培养用作对照手段。细胞因子产生的增加表明在联合使用药物过程中滴眼剂的毒性没有增加，这使得可以使用经证实的药物组合治疗结膜和角膜炎性疾病。当联合使用药物组合时，本发明可用于防止增强滴眼剂毒性的现象。; 5 cl，3 dwg，1 ex，3 tbl

著录项

公开/公告号RU2646100C1

专利类型
公开/公告日2018-03-01

原文格式PDF
申请/专利权人 SUETINA IRINA ALEKSANDROVNA;
展开▼

申请/专利号RU20170124583
发明设计人 SUETINA IRINA ALEKSANDROVNA (RU);CHERNAKOVA GALINA MELSOVNA (RU);MAJCHUK DMITRIJ YUREVICH (RU);RUSSU LEONID IVANOVICH (RU);KLESHCHEVA ELENA ALEKSANDROVNA (RU);MURTAZALIEVA SANIYAT MAGOMEDOVNA (RU);MEZENTSEVA MARINA VLADIMIROVNA (RU);
展开▼

申请日2017-07-11
分类号C12N5/071;G01N33/50;G01N33/53;
国家 RU
入库时间 2022-08-21 12:35:44

相似文献

专利
外文文献
中文文献